Medical device company Control Bionics Ltd (ASX:CBL) has secured an exclusive deal which will see its NeuroNode device distributed throughout the United Kingdom and Ireland through Smart Box Ltd – the UK’s premier provider of assistive technology.
NeuroNode is a wearable device which captures the brain signals being sent to skeletal muscles and transfers this input to a personal computer to enable speech and other functions, and through the agreement with Smart Box, it will now be made available to people with Motor Neurone Disease (MND), cerebral palsy and related conditions.
The contract will be for an initial term of two years, and will see Smart Box UK become exclusive distributor for the wireless product (and its Controller App).
Control Bionics CEO Jeremy Steele said the company was thrilled to see NeuroNode make it to the UK and Irish markets.
“This exclusive agreement marks an exciting step in our mission to empower people with severe disabilities to communicate and regain control of their lives through innovative technology,” he said.
“The NeuroNode has already been paired with hundreds of Smart Box devices and devices with Smart Box software around the world.
“We’re excited to extend this successful relationship to the UK and Ireland for the first time and look forward to building on this strong foundation to enhance the lives of users across these countries.”
“By leveraging Smart Box’s expertise and established network, we are confident that this partnership will accelerate the adoption of NeuroNode® across the UK and Ireland and improve the quality of life for countless individuals with speech and motor
impairments.”
The market seemed pleased with the news, and by 12:05 AEST, Control Bionics shares were trading at 9 cents – a rise of 3.45% since the market opened.